INTRODUCTION
development of cardiovascular disease remain uncertain. However, several pathways which are mediated by endothelial dysfunction, 9 arterial stiffness 5, 10 and inflammation may be involved. 11 Given that hypertension, as a primary part of MetS, is usually accompanied by other cardiometabolic risk factors, 12 it is possible that the cardiovascular risk profiles are greatly exaggerated in the presence of underlying MetS in hypertension, thus possibly leading to increased risks for cardiovascular morbidity and mortality.
In the present study, we hypothesized that the presence of MetS would result in unfavorable patterns for cardiovascular risk profiles in treated hypertensive patients. To test this possibility, we evaluated the inflammatory markers and antioxidant potential together with blood omega 3 fatty acid compositions which have emerged as a risk factor for cardiovascular disease in hypertension with-or without MetS.
Subjects
One hundred thirty-five hypertensive patients who had been diagnosed and treated at Yonsei Cardiovascular Center participated in the present study. Subjects with any of the following conditions were excluded from participation: valvular heart disease, peripheral vascular disease, significant systemic disease, history of inflammatory disease and/or on anti-inflammatory medications, patient taking aldosterone antagonists at the time of study enrollment, clinically significant atrioventricular conduction disturbance, history of atrial fibrillation or other serious arrhythmia, severe hypertension (> 210/130 mmHg) or serum creatinine greater than 1.4 mg/dL. They underwent a brief physical examination for measurement of seated blood pressure using a sphygmomanometer with an appropriate cuff. Two measurements were taken at least five minutes apart and the mean value was used for analysis. Weight was measured using a standard balance beam scale or an electronic scale and height was measured using a height rod of a standard beam scale, or a wall-mounted stadiometer. Body Mass Index (BMI) was calculated as weight in kg divided by height in meters squared. Waist circumference was measured twice to the nearest 0.1 cm with a flexible tape measure at the level of the minimum circumference, usually at the level of the navel. All patients gave written informed consent, and the Institutional Review Board at the Yonsei University Medical Center approved the study protocol.
Classification of MetS
MetS was defined as three or more of the following abnormalities according to modified NCEP ATP III definition (ATP III criteria and the WHO Western Pacific Region obesity criteria) 13, 14 : 1) abdominal obesity, waist circumference ≥ 90 cm in men, ≥ 80 cm in women; 2) hypertriglyceridemia, ≥ 150 mg/dL; 3) high-density lipoprotein (HDL)-cholesterol, < 40 mg/dL in men and < 50 mg/dL in women; 4) hypertension (systolic blood pressure ≥ 130 mmHg or diastolic pressure ≥ 85 mmHg) or on anti-hypertensive medication; 5) high fasting glucose, ≥ 110 mg/dL or under treatment for diabetes.
Serum lipid profiles, glucose, insulin and HOMA Fasting blood samples were taken, and serum cholesterol, low-density lipoprotein (LDL)-cholesterol and HDL-cholesterol were measured by enzymatic methods with commercially available kits (Choongwae, Seoul, Korea). Serum triglyceride levels were analyzed using a total glycerol test kit (Roche, Basel, Switzerland). All determinants were done on a Hitachi 747 auto-analyzer (Hitachi Ltd., Tokyo, Japan). Fasting serum glucose concentrations were measured by the glucose oxidase method using a Beckman Glucose Analyzer (Beckman Instruments, Irvine, CA, USA). The fasting serum insulin level was measured with an immunoradiometric assay and a gamma counter (Hewlett Packard, Meriden, CT, USA). We calculated homeostasis model of insulin resistance (HOMA-IR) using the equation HOMA-IR = fasting insulin (µU/mL) × glucose (mmol/L)/22.5.
15
Conjugated dienes in LDL Baseline LDL conjugated dienes (CD) were determined according to Ahotupa, et al. 16 with little modification. One hundred µL of plasma was added to 700 µL of heparin citrate buffer (0.064 M trisodium citrate, 50,000 IU/L heparin, pH 5.05), and the suspension was allowed to stand for 10 min at room temperature. The insoluble lipoproteins were then sedimented by centrifugation at 1,000 g for 10 min. The pellet was resuspended in 100 µl of 0.1 M Naphosphate buffer containing 0.9% NaCl (pH 7.4). Lipids were extracted from 100 µL of LDL suspension by chloroform-methanol (2 : 1), dried under nitrogen, then redissolved in cyclohexane and analyzed spectrophotometrically at 234 nm. Oxidation during the sample preparation was prevented by adding ethylenediaminetetraacetic acid (EDTA).
Plasma total radical trapping antioxidant potential (TRAP)
TRAP was measured by a modification of the photometric method according to Rice-Evans and Miller. 17 The method for measuring antioxidant activity is based on the antioxidants' inhibition of absorbance of the radical cation, 2,2'-azinobis (3-ethylbenzothiazoline 6-sulfonate) (ABTS + ). The ABTS + radical cation was formed by the interaction of ABTS + (150 µM) with ferrylmyoglobin radical species,
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generated by the activation of metmyoglobin (2.5 µM) with H2O2 (75 µM). Ten µL of sample/buffer/Trolox-standard were added to tubes containing 400 µL of phosphate buffered saline (PBS) buffer, 20 µL of metmyoglobin and 400 µL of ABTS, and the contents were mixed by vortexing. The reaction was initiated by addition of 170 µL of H2O2. Absorbance was measured with a spectrophotometer at 734 nm after 6 min of incubation. Values were expressed as trolox equivalent antioxidant capacity (TEAC), which is defined as mM concentration of Trolox antioxidant capacity, determined by using a calibration curve.
Plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid contents
Total lipids were extracted according to the method of Folch, et al., and the phospholipid fraction was isolated by using thin-layer chromatography with hexane : diethyl ether : acetic acid (80 : 20 : 2) development solvent. The phospholipid fractions were then directly transesterified to prepare fatty acid methyl esters (FAMEs) by the method of Lepage and Roy. 18 The FAME of individual fatty acids of phospholipids was separated on a gas chromatograph (model 6890, Agilent Technologies Inc, Palo Alto, CA, USA) equipped with a capillary column (SP-2560; 100m, Supelco, Bellefonte, PA, USA) as previously described. 19 Peak retention times were identified by comparison with known standard (37 component FAME mix, Supelco, Bellefonte, PA; GLC37, NuCheck Prep, Elysian, MN, USA) and analyzed with the ChemStation software (Agilent Technologies). Plasma phospholipid levels of EPA and DHA were expressed as the percentage of total fatty acids.
Assay of plasma IL-6, ICAM-1, adiponectin, and HMW-adiponectin Plasma interleukin-6 (IL-6, R&D Systems, Minneapolis, MN, USA), intercellular cell adhesion molecule-1 (ICAM-1, R&D Systems, Minneapolis, MN, USA), adiponectin (Linco Research, St. Charles, MO, USA) and high molecular weight adiponectin (HMW-adiponetin, Linco Research, St. Charles, MO, USA) were measured using an enzyme-linked immunoassay according to manufacturer's instructions.
Statistical analysis
The Statistical Package for Social Science (SPSS; SPSS Inc, Chicago, IL, USA) 12.0 software package was used for statistical analysis. Data are presented as mean ± S.E. Each variable was examined for normal distribution, and abnormally distributed variables were log-transformed. Frequency distributions were tested by χ 2 test among the groups. General Linear Model (GLM) was used to test the differences of parameters between the groups after adjusting age and BMI. p values < 0.05 were considered statistically significant.
Of the 135 treated hypertensive subjects, 124 subjects were available for the classification of MetS and further analyzed for this study. Based on the criteria of MetS, two groups were classified by the components of MetS: a reference group of treated hypertensive subjects: HTN group (n = 39) and with more than two additional MetS components: HTN with Mets group (n = 40), and we further compared the parameters between HTN group and HTN with MetS group. The proportions of patients taking these medications were similar between the groups (Table 1) . Table 1 describes baseline characteristics and clinical parameters between HTN group and HTN with MetS group. Age (p < 0.001) and BMI (p < 0.001) were significantly different between the groups. Systolic and diastolic blood pressure and gender distribution were not significantly different. As expected, serum concentrations of TG (p < 0.001) and HDL-cholesterol (p < 0.001) and the levels of HOMA-IR (p < 0.001) were significantly different between the groups. On the other hand, serum concentrations of total cholesterol and LDL-cholesterol were similar between the two groups. Table 2 compares LDL-CD, TRAP, phospholipid DHA and inflammatory markers between the two groups. Because age and BMI were significantly different between the groups, we used the age-and BMI-adjusted values for all analyses. The results showed that age-and BMI-adjusted TRAP (p < 0.01) was significantly lower, whereas age-and BMI-adjusted CD (p < 0.05) was significantly higher in HTN with MetS group than in HTN group. On the other hand, the levels of age-and BMI-adjusted ICAM-1, adiponectin and HMW-adiponectin were not significantly different between the groups.
RESULTS
Moreover, HTN with MetS group had significantly lower levels of age-and BMI-adjusted plasma phospholipid EPA (p < 0.05) and significantly higher levels of ageand BMI-adjusted IL-6 (p < 0.05) than in HTN group, whereas no differences were found in DHA between the two groups (Fig. 1) .
To examine the synergistic effects of MetS in hypertension on cardiovascular risk profiles, we evaluated plasma LDL-CD as a marker for lipid peroxidation, TRAP as a reflection of antioxidant potential, inflammation (IL-6, ICAM-1, total-and HMW-adiponectin) and plasma phospholipid omega 3 fatty acid contents. Our results showed that the levels of LDL-CD and IL-6 were increased whereas the levels of TRAP and plasma phospholipid EPA were decreased in hypertensive patients with MetS compared to those in hypertensive patients.
It is well demonstrated that increased oxidative stress underlies the pathophysiology of hypertension by directly influencing vascular wall cells 20 and oxidative stress has been associated with the onset of cardiovascular complications in subjects with the metabolic syndrome. 21 Several observational and experimental studies showed impaired antioxidant systems with decreases in antioxidant capacity and increases in lipid peroxidation in MetS, 22 which is consistent with our results. Hyperglycemia, a key component of the MetS, might trigger oxidative stress by several mechanisms either independently or associated with other conditions. 23 It includes glucose auto-oxidation, advanced glycated end product (AGE) formation, abnormal arachidonic acid metabolism and its coupling to cyclooxygenase catalysis. 23 The enhanced lipid peroxidation and reduced antioxidant potential in hypertension with MetS, shown in the present study, can be explained, in part, through the mechanisms mentioned above. Considering the atherogenic effect of oxidative alterations in the atherosclerotic process, 24 our results provide a possible mechanism which links MetS in hypertension to increased cardiovascular risks.
DISCUSSION
Inflammation has been established to be a major mediator of increased cardiovascular risks. 25 As evidenced by elevations of circulating levels of C-reactive protein (CRP) and several inflammatory cytokines including IL-6 and tumor necrosis factor-α (TNF-α), chronic inflammation has been associated with hypertension and MetS. 26, 27 Consistent with the earlier findings, 26, 27 we observed in the present study that plasma levels of IL-6 were significantly higher in the hypertensive patients with MetS. Adiponectin, a most abundant adipokine, is primarily released from adipose tissue, and adipose tissue is believed to be an important mediator of oxidative stress and inflammation. 28 The profound metabolic effects of adiponectin on glucose and lipid metabolism provide an evidence to link obesity-related chronic inflammation and atherosclerosis. 28, 29 HMW-adiponectin is a multimeric form of adipoenctin and has been suggested as a more sensitive biomarker for insulin resistance and abdominal adiposity than total adiponectin. 29 In contrast to the previous studies, [28] [29] [30] [31] there were no significant differences in total-and HMW-adiponectin levels between the groups. This may be attributed, in part, to the study population with narrow range in BMI (mean 24.6 kg/m 2 , 20.0-29.8) in the present study. However, we found genderspecific differences in total-and HMW adiponectin between hypertension group and hypertension with MetS group. In females, plasma levels of total-and HMW adiponectin were significantly lower in hypertension with MetS group than hypertension group, but not in males (data not shown). Also, the effect of MetS in hypertension on the levels of TRAP was mainly derived from females (data not shown). Our results partly support that MetS may have different relative importance for cardiovascular disease according to gender, and that the prognostic impact of MetS is better in females than in males. 2, 6, 32 Emerging evidence showed that omega-3 fatty acids (EPA and DHA) have a variety of beneficial effects on blood pressure, platelet aggregation, inflammatory responses and vasodilation as well as lipid and lipoprotein metabolism. 33 Furthermore, omega 3 fatty acids were found to protect cardiovascular morbidity and mortality, 34, 35 suggesting as an emerging risk factor for cardiovascular disease. The mechanisms by which omega 3 fatty acids exhibit cardioprotective effects include that they alter membrane physical characteristics and the activity of membranebound proteins. 36 Furthermore, they can interact with ion channels and also act as ligands for several nuclear transcription factors. 36 The major finding in this study was that plasma phospholipid EPA content was significantly lower in hypertensive patients with MetS than that in hypertensive patients, whereas no difference was observed in DHA. Given that EPA is known to inhibit the production of proinflammatory eicosanoids more efficiently than DHA, 37 it may modulate inflammatory conditions, oxidative stress accompanied by reduced antioxidant potential, which was not experimentally proved in this study. However, only plasma phosholipid EPA, but not DHA, was slightly reduced, therefore, it is also possible to consider potential metabolic alterations. EPA may in part originate from retroconversion of DHA in the peroxisome which requires partial β-oxidation. 38 Thus, diminished levels of EPA and concomitantly enhanced DHA may occur under conditions of reduced peroxisomal β-oxidation in the MetS. Further experimental studies are needed to elucidate the mechanism for these relationships described in this study.
The main limitations of this study are small sample size and cross-sectional setting, thus making it hard to draw causality. Also, we could not exclude the possibility that lack of nutritional information on fatty acids and fish consumption might confound the results. Nevertheless, our results extended several previous studies by showing synergistic effects of MetS in hypertension on inflammation and oxidative stress. Furthermore, we found decreased plasma phospholipid EPA in hypertensive patients with MetS, suggesting possible impact of MetS on inflammatory response in hypertension.
To conclude, our results showed increased inflammatory marker, reduced plasma phospholipid EPA content and reduced antioxidant potential in treated hypertensive patients in the presence of MetS. Considering that blood and tissue omega 3 fatty acids are the reflections of dietary intakes, 36 our results suggest the importance of changes of therapeutic lifestyle to modify the features of MetS. Intensive nutritional program needs to be encouraged in these hypertensive patients with MetS in clinical settings. 
